γ‐Tocopherol‐enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice

γ‐tocopherol (γ‐T) alone or in combination with α‐tocopherol has been shown to suppress biomarkers of oxidative stress in asthamatics and human subjects with metabolic syndrome. Oxidative stress has been implicated as a key event in prostate carcinogenesis. Hence, the purpose of this study was to ex...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of cancer Vol. 124; no. 7; pp. 1693 - 1699
Main Authors Barve, Avantika, Khor, Tin Oo, Nair, Sujit, Reuhl, Kenneth, Suh, Nanjoo, Reddy, Bandaru, Newmark, Harold, Kong, Ah‐Ng
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.04.2009
Subjects
Online AccessGet full text

Cover

Loading…
Abstract γ‐tocopherol (γ‐T) alone or in combination with α‐tocopherol has been shown to suppress biomarkers of oxidative stress in asthamatics and human subjects with metabolic syndrome. Oxidative stress has been implicated as a key event in prostate carcinogenesis. Hence, the purpose of this study was to examine the effects of γ‐tocopherol‐enriched mixed tocopherol diet on prostate carcinogenesis in a murine prostate cancer model (TRAMP). 8 week old TRAMP males were fed 0.1% γ‐T‐enriched mixed tocopherol diet that contained 20‐fold higher levels of γ‐tocopherol, and roughly 3‐fold higher levels of α‐tocopherol. The effect of such diet on tumor and PIN development was observed. The expression of phase II detoxifying, antioxidant enzymes and Nrf2 mRNA and protein were determined by RT‐PCR, immunohistochemistry and western blotting techniques. Treatment with γ‐T‐enriched mixed tocopherols significantly suppressed the incidence of palpable tumor and Prostate Intraepithelial Neoplasia (PIN) development without affecting the expression of the transgene (SV‐40). Tumor progression occurred with a significant suppression of antioxidant enzymes such as catalase, superoxide dismutase, glutathione peroxidase, heme‐oxygenase‐1 and phase II detoxifying enzymes. Treatment with γ‐T‐enriched mixed tocopherol diet upregulated the expression of most detoxifying and antioxidant enzymes. Nrf2—a redox sensitive transcription factor known to mediate the expression of phase II detoxifying enzymes, was also significantly upregulated following treatment with γ‐T‐enriched mixed tocopherol diet. γ‐T‐enriched mixed tocopherols significantly up‐regulated the expression of Nrf2 and its related detoxifying and antioxidant enzymes thereby suppressing PIN and tumor development. © 2008 Wiley‐Liss, Inc.
AbstractList γ-tocopherol (γ-T) alone or in combination with α-tocopherol has been shown to suppress biomarkers of oxidative stress in asthamatics and human subjects with metabolic syndrome. Oxidative stress has been implicated as a key event in prostate carcinogenesis. Hence, the purpose of this study was to examine the effects of γ-tocopherol-enriched mixed tocopherol diet on prostate carcinogenesis in a murine prostate cancer model (TRAMP). 8 week old TRAMP males were fed 0.1% γ -T-enriched mixed tocopherol diet that contained 20-fold higher levels of γ-tocopherol, and roughly 3-fold higher levels of α-tocopherol. The effect of such diet on tumor and PIN development was observed. The expression of phase II detoxifying, antioxidant enzymes and Nrf2 mRNA and protein were determined by RT-PCR, immunohistochemistry and western blotting techniques. Treatment with γ-T-enriched mixed tocopherols significantly suppressed the incidence of palpable tumor and Prostate Intraepithelial Neoplasia (PIN) development without affecting the expression of the transgene (SV-40). Tumor progression occurred with a significant suppression of antioxidant enzymes such as catalase, superoxide dismutase, glutathione peroxidase, heme-oxygenase-1 and phase II detoxifying enzymes. Treatment with γ-T-enriched mixed tocopherol diet upregulated the expression of most detoxifying and antioxidant enzymes. Nrf2—a redox sensitive transcription factor known to mediate the expression of phase II detoxifying enzymes, was also significantly upregulated following treatment with γ-T-enriched mixed tocopherol diet. γ-T-enriched mixed tocopherols significantly up-regulated the expression of Nrf2 and its related detoxifying and antioxidant enzymes thereby suppressing PIN and tumor development.
γ‐tocopherol (γ‐T) alone or in combination with α‐tocopherol has been shown to suppress biomarkers of oxidative stress in asthamatics and human subjects with metabolic syndrome. Oxidative stress has been implicated as a key event in prostate carcinogenesis. Hence, the purpose of this study was to examine the effects of γ‐tocopherol‐enriched mixed tocopherol diet on prostate carcinogenesis in a murine prostate cancer model (TRAMP). 8 week old TRAMP males were fed 0.1% γ‐T‐enriched mixed tocopherol diet that contained 20‐fold higher levels of γ‐tocopherol, and roughly 3‐fold higher levels of α‐tocopherol. The effect of such diet on tumor and PIN development was observed. The expression of phase II detoxifying, antioxidant enzymes and Nrf2 mRNA and protein were determined by RT‐PCR, immunohistochemistry and western blotting techniques. Treatment with γ‐T‐enriched mixed tocopherols significantly suppressed the incidence of palpable tumor and Prostate Intraepithelial Neoplasia (PIN) development without affecting the expression of the transgene (SV‐40). Tumor progression occurred with a significant suppression of antioxidant enzymes such as catalase, superoxide dismutase, glutathione peroxidase, heme‐oxygenase‐1 and phase II detoxifying enzymes. Treatment with γ‐T‐enriched mixed tocopherol diet upregulated the expression of most detoxifying and antioxidant enzymes. Nrf2—a redox sensitive transcription factor known to mediate the expression of phase II detoxifying enzymes, was also significantly upregulated following treatment with γ‐T‐enriched mixed tocopherol diet. γ‐T‐enriched mixed tocopherols significantly up‐regulated the expression of Nrf2 and its related detoxifying and antioxidant enzymes thereby suppressing PIN and tumor development. © 2008 Wiley‐Liss, Inc.
Gamma-tocopherol (gamma-T) alone or in combination with alpha-tocopherol has been shown to suppress biomarkers of oxidative stress in asthamatics and human subjects with metabolic syndrome. Oxidative stress has been implicated as a key event in prostate carcinogenesis. Hence, the purpose of this study was to examine the effects of gamma-tocopherol-enriched mixed tocopherol diet on prostate carcinogenesis in a murine prostate cancer model (TRAMP). 8 week old TRAMP males were fed 0.1% gamma-T-enriched mixed tocopherol diet that contained 20-fold higher levels of gamma-tocopherol, and roughly 3-fold higher levels of alpha-tocopherol. The effect of such diet on tumor and PIN development was observed. The expression of phase II detoxifying, antioxidant enzymes and Nrf2 mRNA and protein were determined by RT-PCR, immunohistochemistry and western blotting techniques. Treatment with gamma-T-enriched mixed tocopherols significantly suppressed the incidence of palpable tumor and Prostate Intraepithelial Neoplasia (PIN) development without affecting the expression of the transgene (SV-40). Tumor progression occurred with a significant suppression of antioxidant enzymes such as catalase, superoxide dismutase, glutathione peroxidase, heme-oxygenase-1 and phase II detoxifying enzymes. Treatment with gamma-T-enriched mixed tocopherol diet upregulated the expression of most detoxifying and antioxidant enzymes. Nrf2-a redox sensitive transcription factor known to mediate the expression of phase II detoxifying enzymes, was also significantly upregulated following treatment with gamma-T-enriched mixed tocopherol diet. Gamma-T-enriched mixed tocopherols significantly up-regulated the expression of Nrf2 and its related detoxifying and antioxidant enzymes thereby suppressing PIN and tumor development.
-tocopherol (-T) alone or in combination with -tocopherol has been shown to suppress biomarkers of oxidative stress in asthamatics and human subjects with metabolic syndrome. Oxidative stress has been implicated as a key event in prostate carcinogenesis. Hence, the purpose of this study was to examine the effects of -tocopherol-enriched mixed tocopherol diet on prostate carcinogenesis in a murine prostate cancer model (TRAMP). 8 week old TRAMP males were fed 0.1% -T-enriched mixed tocopherol diet that contained 20-fold higher levels of -tocopherol, and roughly 3-fold higher levels of -tocopherol. The effect of such diet on tumor and PIN development was observed. The expression of phase II detoxifying, antioxidant enzymes and Nrf2 mRNA and protein were determined by RT-PCR, immunohistochemistry and western blotting techniques. Treatment with -T-enriched mixed tocopherols significantly suppressed the incidence of palpable tumor and Prostate Intraepithelial Neoplasia (PIN) development without affecting the expression of the transgene (SV-40). Tumor progression occurred with a significant suppression of antioxidant enzymes such as catalase, superoxide dismutase, glutathione peroxidase, heme-oxygenase-1 and phase II detoxifying enzymes. Treatment with -T-enriched mixed tocopherol diet upregulated the expression of most detoxifying and antioxidant enzymes. Nrf2 - a redox sensitive transcription factor known to mediate the expression of phase II detoxifying enzymes, was also significantly upregulated following treatment with -T-enriched mixed tocopherol diet. -T-enriched mixed tocopherols significantly up-regulated the expression of Nrf2 and its related detoxifying and antioxidant enzymes thereby suppressing PIN and tumor development.
Gamma-tocopherol (gamma-T) alone or in combination with alpha-tocopherol has been shown to suppress biomarkers of oxidative stress in asthamatics and human subjects with metabolic syndrome. Oxidative stress has been implicated as a key event in prostate carcinogenesis. Hence, the purpose of this study was to examine the effects of gamma-tocopherol-enriched mixed tocopherol diet on prostate carcinogenesis in a murine prostate cancer model (TRAMP). 8 week old TRAMP males were fed 0.1% gamma-T-enriched mixed tocopherol diet that contained 20-fold higher levels of gamma-tocopherol, and roughly 3-fold higher levels of alpha-tocopherol. The effect of such diet on tumor and PIN development was observed. The expression of phase II detoxifying, antioxidant enzymes and Nrf2 mRNA and protein were determined by RT-PCR, immunohistochemistry and western blotting techniques. Treatment with gamma-T-enriched mixed tocopherols significantly suppressed the incidence of palpable tumor and Prostate Intraepithelial Neoplasia (PIN) development without affecting the expression of the transgene (SV-40). Tumor progression occurred with a significant suppression of antioxidant enzymes such as catalase, superoxide dismutase, glutathione peroxidase, heme-oxygenase-1 and phase II detoxifying enzymes. Treatment with gamma-T-enriched mixed tocopherol diet upregulated the expression of most detoxifying and antioxidant enzymes. Nrf2-a redox sensitive transcription factor known to mediate the expression of phase II detoxifying enzymes, was also significantly upregulated following treatment with gamma-T-enriched mixed tocopherol diet. Gamma-T-enriched mixed tocopherols significantly up-regulated the expression of Nrf2 and its related detoxifying and antioxidant enzymes thereby suppressing PIN and tumor development.Gamma-tocopherol (gamma-T) alone or in combination with alpha-tocopherol has been shown to suppress biomarkers of oxidative stress in asthamatics and human subjects with metabolic syndrome. Oxidative stress has been implicated as a key event in prostate carcinogenesis. Hence, the purpose of this study was to examine the effects of gamma-tocopherol-enriched mixed tocopherol diet on prostate carcinogenesis in a murine prostate cancer model (TRAMP). 8 week old TRAMP males were fed 0.1% gamma-T-enriched mixed tocopherol diet that contained 20-fold higher levels of gamma-tocopherol, and roughly 3-fold higher levels of alpha-tocopherol. The effect of such diet on tumor and PIN development was observed. The expression of phase II detoxifying, antioxidant enzymes and Nrf2 mRNA and protein were determined by RT-PCR, immunohistochemistry and western blotting techniques. Treatment with gamma-T-enriched mixed tocopherols significantly suppressed the incidence of palpable tumor and Prostate Intraepithelial Neoplasia (PIN) development without affecting the expression of the transgene (SV-40). Tumor progression occurred with a significant suppression of antioxidant enzymes such as catalase, superoxide dismutase, glutathione peroxidase, heme-oxygenase-1 and phase II detoxifying enzymes. Treatment with gamma-T-enriched mixed tocopherol diet upregulated the expression of most detoxifying and antioxidant enzymes. Nrf2-a redox sensitive transcription factor known to mediate the expression of phase II detoxifying enzymes, was also significantly upregulated following treatment with gamma-T-enriched mixed tocopherol diet. Gamma-T-enriched mixed tocopherols significantly up-regulated the expression of Nrf2 and its related detoxifying and antioxidant enzymes thereby suppressing PIN and tumor development.
Author Barve, Avantika
Reddy, Bandaru
Kong, Ah‐Ng
Khor, Tin Oo
Suh, Nanjoo
Nair, Sujit
Reuhl, Kenneth
Newmark, Harold
AuthorAffiliation 3 Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ
2 Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ
1 Graduate Program in Pharmaceutical Sciences, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ
5 Center for Cancer Prevention Research, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ
4 Department for Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ
AuthorAffiliation_xml – name: 4 Department for Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ
– name: 5 Center for Cancer Prevention Research, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ
– name: 1 Graduate Program in Pharmaceutical Sciences, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ
– name: 2 Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ
– name: 3 Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ
Author_xml – sequence: 1
  givenname: Avantika
  surname: Barve
  fullname: Barve, Avantika
– sequence: 2
  givenname: Tin Oo
  surname: Khor
  fullname: Khor, Tin Oo
– sequence: 3
  givenname: Sujit
  surname: Nair
  fullname: Nair, Sujit
– sequence: 4
  givenname: Kenneth
  surname: Reuhl
  fullname: Reuhl, Kenneth
– sequence: 5
  givenname: Nanjoo
  surname: Suh
  fullname: Suh, Nanjoo
– sequence: 6
  givenname: Bandaru
  surname: Reddy
  fullname: Reddy, Bandaru
– sequence: 7
  givenname: Harold
  surname: Newmark
  fullname: Newmark, Harold
– sequence: 8
  givenname: Ah‐Ng
  surname: Kong
  fullname: Kong, Ah‐Ng
  email: kongt@rci.rutgers.edu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19115203$$D View this record in MEDLINE/PubMed
BookMark eNqFkc1OGzEUhS0EgkC74AXQrCqxGLA9Hs94UwlF_aECFVXp2rI9N-SiiZ3ak1J2fYS-S9-jD9EnqWnSqCCqbvyj-52jo3v2ybYPHgg5ZPSEUcpP8cadcMGo3CIjRlVTUs7qbTLKM1o2rJJ7ZD-lG0oZq6nYJXtM5Ren1YjoH99_fv02CS4sZhBDnz_gI7oZdMUcv-Rz2MyKDmEo0M_Q4pCKRQxpMAMUzkSHPlyDh4QpA8Xkw9nlVdY7eEZ2pqZP8Hx9H5CPr19Nxm_Li_dvzsdnF6UTQsiyamXLuLCiAqhV3VgrG9k54Jwba6jijQPGlJky2kFtZKeUmyorTaOk5NZWB-TlynextHPISj9E0-tFxLmJdzoY1A8nHmf6OnzWQiol6zYbvFgbxPBpCWnQc0wO-t54CMukpWwbJVj9X5BTyVuhRAaP_o60yfJn-Rk4XQEubzJFmGqHeaEY7hNirxnV9_XqXK_-XW9WHD9SbEyfYNfut9jD3b9Bff5uvFL8AhD2uFg
CitedBy_id crossref_primary_10_1158_1940_6207_CAPR_09_0237
crossref_primary_10_1002_mc_22164
crossref_primary_10_1002_mc_23299
crossref_primary_10_1158_1940_6207_CAPR_10_0107
crossref_primary_10_1002_biof_1200
crossref_primary_10_3390_ijms17122107
crossref_primary_10_1021_jf501944u
crossref_primary_10_3390_ph17050597
crossref_primary_10_1371_journal_pone_0008579
crossref_primary_10_3390_antiox12030771
crossref_primary_10_1002_jssc_202300285
crossref_primary_10_3390_nu10070801
crossref_primary_10_1021_tx300524p
crossref_primary_10_1016_j_advnut_2024_100240
crossref_primary_10_1016_j_bcp_2011_12_027
crossref_primary_10_1038_cgt_2014_45
crossref_primary_10_1007_s10126_020_09982_3
crossref_primary_10_1016_j_canlet_2015_11_010
crossref_primary_10_1093_carcin_bgp205
crossref_primary_10_3390_cancers10100352
crossref_primary_10_1080_01635581_2012_649100
crossref_primary_10_1208_s12248_013_9493_3
crossref_primary_10_1016_j_freeradbiomed_2013_02_008
crossref_primary_10_1002_mnfr_201500847
crossref_primary_10_3390_nu15153347
crossref_primary_10_1002_pros_21360
crossref_primary_10_1016_j_bcp_2013_02_010
crossref_primary_10_3945_jn_111_153114
crossref_primary_10_1002_biof_75
crossref_primary_10_1111_j_1749_6632_2010_05561_x
crossref_primary_10_1158_1940_6207_CAPR_11_0521
crossref_primary_10_1111_iep_12042
crossref_primary_10_1158_1940_6207_CAPR_13_0313_T
crossref_primary_10_1158_1940_6207_CAPR_12_0263
crossref_primary_10_1016_j_biopha_2016_04_022
crossref_primary_10_3390_ijms25158250
crossref_primary_10_3945_an_117_016329
crossref_primary_10_1002_mc_22776
crossref_primary_10_1002_mc_21886
crossref_primary_10_1007_s11095_009_9948_5
crossref_primary_10_34172_jhp_2020_15
crossref_primary_10_1016_j_bcp_2011_07_065
crossref_primary_10_1016_j_biochi_2013_04_012
crossref_primary_10_1016_j_freeradbiomed_2021_12_012
crossref_primary_10_3390_ijms131012349
crossref_primary_10_1089_ars_2010_3276
crossref_primary_10_4103_2225_4110_107700
crossref_primary_10_1021_jf401076g
crossref_primary_10_1016_j_freeradbiomed_2014_03_035
crossref_primary_10_1007_s10549_011_1604_1
crossref_primary_10_1002_ange_201107724
crossref_primary_10_1002_fsn3_1154
crossref_primary_10_1186_1743_7075_11_52
crossref_primary_10_1134_S0006297922050030
crossref_primary_10_1002_ijc_26054
crossref_primary_10_3390_antiox11020183
crossref_primary_10_3390_cancers3043762
crossref_primary_10_1021_tx4004038
crossref_primary_10_1016_S0003_9098_25_01538_3
crossref_primary_10_3390_ijms221810087
crossref_primary_10_1007_s11033_022_08052_2
crossref_primary_10_7314_APJCP_2014_15_5_1897
crossref_primary_10_1097_MED_0b013e328339f31e
crossref_primary_10_3390_molecules15031762
crossref_primary_10_1002_mc_20841
crossref_primary_10_2119_molmed_2010_00136
crossref_primary_10_1093_carcin_bgr261
crossref_primary_10_1002_mc_22422
crossref_primary_10_1080_01635581_2020_1857412
crossref_primary_10_1089_ars_2012_4662
crossref_primary_10_18632_oncotarget_1979
crossref_primary_10_1038_onc_2010_118
crossref_primary_10_1093_carcin_bgx128
crossref_primary_10_1002_mc_23160
crossref_primary_10_1016_j_freeradbiomed_2015_06_013
crossref_primary_10_1016_j_freeradbiomed_2011_12_005
crossref_primary_10_1158_1940_6207_CAPR_10_0130
crossref_primary_10_3390_nu13020496
crossref_primary_10_3390_nu3110962
crossref_primary_10_1016_j_cca_2014_06_004
crossref_primary_10_1016_j_mad_2010_03_005
crossref_primary_10_1158_1940_6207_CAPR_12_0045
crossref_primary_10_1002_anie_201107724
crossref_primary_10_1016_j_canlet_2012_06_007
crossref_primary_10_1080_01635581003605896
crossref_primary_10_18632_oncotarget_17997
crossref_primary_10_1093_carcin_bgp332
crossref_primary_10_1016_j_arr_2014_01_001
crossref_primary_10_1016_j_canlet_2013_01_051
Cites_doi 10.1016/j.juro.2007.03.138
10.1074/jbc.M607622200
10.1016/j.clinbiochem.2005.11.018
10.1016/j.freeradbiomed.2007.12.018
10.1207/s15327914nc5601_11
10.3109/10408449309117115
10.1016/j.mrfmmm.2005.04.017
10.1080/01635580701419022
10.1016/j.mrfmmm.2004.06.041
10.1073/pnas.90.5.1771
10.1016/j.humpath.2007.02.008
10.1093/jnci/92.24.2018
10.1158/1055-9965.EPI-07-0160
10.1158/0008-5472.CAN-05-1334
10.1016/S1040-8428(03)00042-8
10.1158/1055-9965.EPI-04-0679
10.1016/j.freeradbiomed.2004.02.074
10.1016/j.urology.2003.09.053
10.1016/S0002-9440(10)64228-9
10.1111/j.1745-7262.2007.00236.x
10.1081/GNC-120037931
10.1152/ajplung.00361.2007
10.1016/j.ejca.2004.09.028
10.1016/0006-2952(95)02157-4
10.1096/fj.02-0362fje
10.1096/fj.02-0877com
10.1073/pnas.200357097
10.1016/j.pathophys.2006.05.003
10.1002/cncr.20408
ContentType Journal Article
Copyright Copyright © 2008 Wiley‐Liss, Inc.
Copyright_xml – notice: Copyright © 2008 Wiley‐Liss, Inc.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7U7
C1K
7X8
5PM
DOI 10.1002/ijc.24106
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Toxicology Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Toxicology Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList

CrossRef
MEDLINE
Toxicology Abstracts
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1097-0215
EndPage 1699
ExternalDocumentID PMC4699658
19115203
10_1002_ijc_24106
IJC24106
Genre article
Journal Article
GrantInformation_xml – fundername: NIEHS NIH HHS
  grantid: P30 ES005022
GroupedDBID ---
-~X
.3N
.55
.GA
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABIJN
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUYR
AFBPY
AFFPM
AFGKR
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
EX3
F00
F01
F04
F5P
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HGLYW
HHY
HHZ
HZ~
IH2
IX1
J0M
JPC
KBYEO
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
ROL
RX1
RYL
SUPJJ
TEORI
UB1
UDS
V2E
V8K
V9Y
W2D
W8V
W99
WBKPD
WHWMO
WIB
WIH
WIJ
WIK
WJL
WOHZO
WOW
WQJ
WVDHM
WXI
WXSBR
X7M
XG1
XPP
XV2
ZZTAW
~IA
~WT
.GJ
3O-
8WZ
A6W
AANHP
AAYXX
ABEFU
ABEML
ACBWZ
ACRPL
ACSCC
ACYXJ
ADNMO
AEYWJ
AGHNM
AGQPQ
AGYGG
AHEFC
AI.
ASPBG
AVWKF
AZFZN
BDRZF
CITATION
EMOBN
FEDTE
GLUZI
HVGLF
M6P
PALCI
SAMSI
VH1
Y6R
ZGI
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
7U7
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
C1K
7X8
5PM
ID FETCH-LOGICAL-c4446-3868124b43ee5957bb676dce222aba0927ce119af10de5a6d99cf9b6a79662bb3
IEDL.DBID DR2
ISSN 0020-7136
1097-0215
IngestDate Thu Aug 21 14:03:20 EDT 2025
Fri Jul 11 03:18:19 EDT 2025
Fri Jul 11 00:35:56 EDT 2025
Thu Apr 03 06:59:40 EDT 2025
Thu Apr 24 22:56:57 EDT 2025
Tue Jul 01 02:27:23 EDT 2025
Wed Apr 02 05:42:47 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4446-3868124b43ee5957bb676dce222aba0927ce119af10de5a6d99cf9b6a79662bb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.24106
PMID 19115203
PQID 20628494
PQPubID 23462
PageCount 7
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4699658
proquest_miscellaneous_66879415
proquest_miscellaneous_20628494
pubmed_primary_19115203
crossref_citationtrail_10_1002_ijc_24106
crossref_primary_10_1002_ijc_24106
wiley_primary_10_1002_ijc_24106_IJC24106
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 1 April 2009
2009-04-00
2009-Apr-01
20090401
PublicationDateYYYYMMDD 2009-04-01
PublicationDate_xml – month: 04
  year: 2009
  text: 1 April 2009
  day: 01
PublicationDecade 2000
PublicationPlace Hoboken
PublicationPlace_xml – name: Hoboken
– name: United States
PublicationTitle International journal of cancer
PublicationTitleAlternate Int J Cancer
PublicationYear 2009
Publisher Wiley Subscription Services, Inc., A Wiley Company
Publisher_xml – name: Wiley Subscription Services, Inc., A Wiley Company
References 2004; 101
2002; 16
2004; 22
1993; 23
2005; 591
2006; 56
2007; 282
2006; 13
2006; 39
2005; 41
2000; 92
2005; 65
1996; 51
2003; 17
1993; 90
2007; 59
2007; 38
2007; 16
2007; 178
2002; 161
2004; 555
2004; 36
2000; 97
2007; 9
2003; 47
2008; 44
2003; 62
2008; 294
2005; 14
e_1_2_5_26_2
e_1_2_5_27_2
e_1_2_5_24_2
e_1_2_5_25_2
e_1_2_5_22_2
e_1_2_5_23_2
e_1_2_5_20_2
e_1_2_5_21_2
Kang D (e_1_2_5_29_2) 2007; 16
e_1_2_5_28_2
e_1_2_5_14_2
e_1_2_5_13_2
e_1_2_5_9_2
e_1_2_5_16_2
e_1_2_5_8_2
e_1_2_5_15_2
e_1_2_5_7_2
e_1_2_5_10_2
e_1_2_5_6_2
e_1_2_5_5_2
e_1_2_5_12_2
e_1_2_5_4_2
e_1_2_5_11_2
e_1_2_5_3_2
e_1_2_5_2_2
e_1_2_5_18_2
e_1_2_5_17_2
e_1_2_5_19_2
e_1_2_5_30_2
14607218 - Urology. 2003 Nov;62(5 Suppl 1):55-62
15495199 - Cancer. 2004 Nov 15;101(10 Suppl):2371-490
15110384 - Free Radic Biol Med. 2004 May 15;36(10):1199-207
17927505 - Nutr Cancer. 2007;59(1):76-81
11005841 - Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11494-9
17646272 - Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1581-6
17555796 - Hum Pathol. 2007 Sep;38(9):1394-401
12724340 - FASEB J. 2003 May;17(8):816-22
16413012 - Clin Biochem. 2006 Feb;39(2):176-9
8329114 - Crit Rev Toxicol. 1993;23(2):147-69
15617991 - Eur J Cancer. 2005 Jan;41(1):61-70
16030104 - Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1697-702
16814530 - Pathophysiology. 2006 Aug;13(3):143-9
12368234 - FASEB J. 2002 Dec;16(14):1952-4
17644117 - J Urol. 2007 Sep;178(3 Pt 2):S9-S13
8534273 - Biochem Pharmacol. 1996 Jan 12;51(1):87-90
8446589 - Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1771-5
15476857 - Mutat Res. 2004 Nov 2;555(1-2):133-48
17334589 - Asian J Androl. 2007 Mar;9(2):206-12
17127771 - J Biol Chem. 2007 Jan 26;282(4):2529-37
18162601 - Am J Physiol Lung Cell Mol Physiol. 2008 Mar;294(3):L478-88
16054659 - Mutat Res. 2005 Dec 11;591(1-2):93-102
11121464 - J Natl Cancer Inst. 2000 Dec 20;92(24):2018-23
17176221 - Nutr Cancer. 2006;56(1):82-5
16267002 - Cancer Res. 2005 Nov 1;65(21):9807-16
15845219 - J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2004 May;22(1):1-12
12962899 - Crit Rev Oncol Hematol. 2003 Sep;47(3):249-59
18191645 - Free Radic Biol Med. 2008 Mar 15;44(6):1203-8
12163397 - Am J Pathol. 2002 Aug;161(2):727-35
References_xml – volume: 92
  start-page: 2018
  year: 2000
  end-page: 23
  article-title: Association between alpha‐tocopherol, gamma‐tocopherol, selenium, and subsequent prostate cancer
  publication-title: J Natl Cancer Inst
– volume: 41
  start-page: 61
  year: 2005
  end-page: 70
  article-title: Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies
  publication-title: Eur J Cancer
– volume: 16
  start-page: 1581
  year: 2007
  end-page: 6
  article-title: Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study
  publication-title: Cancer Epidemiol Biomarkers Prev
– volume: 591
  start-page: 93
  year: 2005
  end-page: 102
  article-title: Nrf2 as a target for cancer chemoprevention
  publication-title: Mutat Res
– volume: 178
  start-page: S9
  year: 2007
  end-page: 13
  article-title: Chemoprevention of prostate cancer: agents and study designs
  publication-title: J Urol
– volume: 44
  start-page: 1203
  year: 2008
  end-page: 8
  article-title: Gamma‐tocopherol supplementation alone and in combination with alpha‐tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome
  publication-title: Free Radic Biol Med
– volume: 36
  start-page: 1199
  year: 2004
  end-page: 207
  article-title: Nrf2 signaling in coordinated activation of antioxidant gene expression
  publication-title: Free Radic Biol Med
– volume: 555
  start-page: 133
  year: 2004
  end-page: 48
  article-title: Chemoprevention through the Keap1‐Nrf2 signaling pathway by phase 2 enzyme inducers
  publication-title: Mutat Res
– volume: 38
  start-page: 1394
  year: 2007
  end-page: 401
  article-title: Glutathione S‐transferase: differential expression of alpha, mu, and pi isoenzymes in benign prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma
  publication-title: Hum Pathol
– volume: 282
  start-page: 2529
  year: 2007
  end-page: 37
  article-title: Novel n‐3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3
  publication-title: J Biol Chem
– volume: 23
  start-page: 147
  year: 1993
  end-page: 69
  article-title: The role of metabolism in the antioxidant function of vitamin E
  publication-title: Crit Rev Toxicol
– volume: 97
  start-page: 11494
  year: 2000
  end-page: 9
  article-title: Ames BN gamma‐tocopherol and its major metabolite, in contrast to alpha‐tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells
  publication-title: Proc Natl Acad Sci USA
– volume: 16
  start-page: 1952
  year: 2002
  end-page: 4
  article-title: Gamma‐tocopherol inhibits human cancer cell cycle progression and cell proliferation by down‐regulation of cyclins
  publication-title: Faseb J
– volume: 101
  start-page: 2371
  year: 2004
  end-page: 490
  article-title: Human prostate cancer risk factors
  publication-title: Cancer
– volume: 39
  start-page: 176
  year: 2006
  end-page: 9
  article-title: Oxidative stress and antioxidant status in non‐metastatic prostate cancer and benign prostatic hyperplasia
  publication-title: Clin Biochem
– volume: 161
  start-page: 727
  year: 2002
  end-page: 35
  article-title: Prostatic intraepithelial neoplasia in genetically engineered mice
  publication-title: Am J Pathol
– volume: 22
  start-page: 1
  year: 2004
  end-page: 12
  article-title: Mitochondrial mutagenesis and oxidative stress in human prostate cancer
  publication-title: J Environ Sci Health C Environ Carcinog Ecotoxicol Rev
– volume: 65
  start-page: 9807
  year: 2005
  end-page: 16
  article-title: Tocopherol‐associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3‐kinase pathway
  publication-title: Cancer Res
– volume: 56
  start-page: 82
  year: 2006
  end-page: 5
  article-title: Mixed tocopherols inhibit azoxymethane‐induced aberrant crypt foci in rats
  publication-title: Nutr Cancer
– volume: 9
  start-page: 206
  year: 2007
  end-page: 12
  article-title: Reduced expression of alpha‐tocopherol‐associated protein is associated with tumor cell proliferation and the increased risk of prostate cancer recurrence
  publication-title: Asian J Androl
– volume: 294
  start-page: L478
  year: 2008
  end-page: 88
  article-title: Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke‐mediated oxidative stress in human lung epithelial cells
  publication-title: Am J Physiol Lung Cell Mol Physiol
– volume: 62
  start-page: 55
  year: 2003
  end-page: 62
  article-title: Human prostate cancer precursors and pathobiology
  publication-title: Urology
– volume: 13
  start-page: 143
  year: 2006
  end-page: 9
  article-title: Vitamin E biokinetics, oxidative stress and cigarette smoking
  publication-title: Pathophysiology
– volume: 47
  start-page: 249
  year: 2003
  end-page: 59
  article-title: Development of gamma (gamma)‐tocopherol as a colorectal cancer chemopreventive agent
  publication-title: Crit Rev Oncol Hematol
– volume: 51
  start-page: 87
  year: 1996
  end-page: 90
  article-title: Glutathione and glutathione S‐transferase in benign and malignant prostate cell lines and prostate tissues
  publication-title: Biochem Pharmacol
– volume: 17
  start-page: 816
  year: 2003
  end-page: 22
  article-title: Gamma‐tocopherol, but not alpha‐tocopherol, decreases proinflammatory eicosanoids and inflammation damage in rats
  publication-title: Faseb J
– volume: 90
  start-page: 1771
  year: 1993
  end-page: 5
  article-title: Gamma‐tocopherol detoxification of nitrogen dioxide: superiority to alpha‐tocopherol
  publication-title: Proc Natl Acad Sci USA
– volume: 14
  start-page: 1697
  year: 2005
  end-page: 702
  article-title: Changes in serum proteomic patterns by presurgical alpha‐tocopherol and L‐selenomethionine supplementation in prostate cancer
  publication-title: Cancer Epidemiol Biomarkers Prev
– volume: 59
  start-page: 76
  year: 2007
  end-page: 81
  article-title: Mixed tocopherols inhibit N‐methyl‐N‐nitrosourea‐induced mammary tumor growth in rats
  publication-title: Nutr Cancer
– ident: e_1_2_5_6_2
  doi: 10.1016/j.juro.2007.03.138
– ident: e_1_2_5_28_2
  doi: 10.1074/jbc.M607622200
– ident: e_1_2_5_30_2
  doi: 10.1016/j.clinbiochem.2005.11.018
– ident: e_1_2_5_13_2
  doi: 10.1016/j.freeradbiomed.2007.12.018
– ident: e_1_2_5_11_2
  doi: 10.1207/s15327914nc5601_11
– ident: e_1_2_5_7_2
  doi: 10.3109/10408449309117115
– ident: e_1_2_5_22_2
  doi: 10.1016/j.mrfmmm.2005.04.017
– ident: e_1_2_5_12_2
  doi: 10.1080/01635580701419022
– ident: e_1_2_5_21_2
  doi: 10.1016/j.mrfmmm.2004.06.041
– ident: e_1_2_5_18_2
  doi: 10.1073/pnas.90.5.1771
– ident: e_1_2_5_25_2
  doi: 10.1016/j.humpath.2007.02.008
– ident: e_1_2_5_14_2
  doi: 10.1093/jnci/92.24.2018
– volume: 16
  start-page: 1581
  year: 2007
  ident: e_1_2_5_29_2
  article-title: Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-07-0160
– ident: e_1_2_5_9_2
  doi: 10.1158/0008-5472.CAN-05-1334
– ident: e_1_2_5_17_2
  doi: 10.1016/S1040-8428(03)00042-8
– ident: e_1_2_5_10_2
  doi: 10.1158/1055-9965.EPI-04-0679
– ident: e_1_2_5_23_2
  doi: 10.1016/j.freeradbiomed.2004.02.074
– ident: e_1_2_5_5_2
  doi: 10.1016/j.urology.2003.09.053
– ident: e_1_2_5_20_2
  doi: 10.1016/S0002-9440(10)64228-9
– ident: e_1_2_5_8_2
  doi: 10.1111/j.1745-7262.2007.00236.x
– ident: e_1_2_5_4_2
  doi: 10.1081/GNC-120037931
– ident: e_1_2_5_24_2
  doi: 10.1152/ajplung.00361.2007
– ident: e_1_2_5_2_2
  doi: 10.1016/j.ejca.2004.09.028
– ident: e_1_2_5_26_2
  doi: 10.1016/0006-2952(95)02157-4
– ident: e_1_2_5_19_2
  doi: 10.1096/fj.02-0362fje
– ident: e_1_2_5_15_2
  doi: 10.1096/fj.02-0877com
– ident: e_1_2_5_16_2
  doi: 10.1073/pnas.200357097
– ident: e_1_2_5_27_2
  doi: 10.1016/j.pathophys.2006.05.003
– ident: e_1_2_5_3_2
  doi: 10.1002/cncr.20408
– reference: 16814530 - Pathophysiology. 2006 Aug;13(3):143-9
– reference: 16267002 - Cancer Res. 2005 Nov 1;65(21):9807-16
– reference: 15617991 - Eur J Cancer. 2005 Jan;41(1):61-70
– reference: 17127771 - J Biol Chem. 2007 Jan 26;282(4):2529-37
– reference: 11005841 - Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11494-9
– reference: 12724340 - FASEB J. 2003 May;17(8):816-22
– reference: 17176221 - Nutr Cancer. 2006;56(1):82-5
– reference: 15110384 - Free Radic Biol Med. 2004 May 15;36(10):1199-207
– reference: 16030104 - Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1697-702
– reference: 15476857 - Mutat Res. 2004 Nov 2;555(1-2):133-48
– reference: 11121464 - J Natl Cancer Inst. 2000 Dec 20;92(24):2018-23
– reference: 17927505 - Nutr Cancer. 2007;59(1):76-81
– reference: 12163397 - Am J Pathol. 2002 Aug;161(2):727-35
– reference: 12368234 - FASEB J. 2002 Dec;16(14):1952-4
– reference: 18191645 - Free Radic Biol Med. 2008 Mar 15;44(6):1203-8
– reference: 8446589 - Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1771-5
– reference: 18162601 - Am J Physiol Lung Cell Mol Physiol. 2008 Mar;294(3):L478-88
– reference: 17644117 - J Urol. 2007 Sep;178(3 Pt 2):S9-S13
– reference: 14607218 - Urology. 2003 Nov;62(5 Suppl 1):55-62
– reference: 8329114 - Crit Rev Toxicol. 1993;23(2):147-69
– reference: 12962899 - Crit Rev Oncol Hematol. 2003 Sep;47(3):249-59
– reference: 16413012 - Clin Biochem. 2006 Feb;39(2):176-9
– reference: 15495199 - Cancer. 2004 Nov 15;101(10 Suppl):2371-490
– reference: 8534273 - Biochem Pharmacol. 1996 Jan 12;51(1):87-90
– reference: 17555796 - Hum Pathol. 2007 Sep;38(9):1394-401
– reference: 17646272 - Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1581-6
– reference: 17334589 - Asian J Androl. 2007 Mar;9(2):206-12
– reference: 16054659 - Mutat Res. 2005 Dec 11;591(1-2):93-102
– reference: 15845219 - J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2004 May;22(1):1-12
SSID ssj0011504
Score 2.3034697
Snippet γ‐tocopherol (γ‐T) alone or in combination with α‐tocopherol has been shown to suppress biomarkers of oxidative stress in asthamatics and human subjects with...
Gamma-tocopherol (gamma-T) alone or in combination with alpha-tocopherol has been shown to suppress biomarkers of oxidative stress in asthamatics and human...
-tocopherol (-T) alone or in combination with -tocopherol has been shown to suppress biomarkers of oxidative stress in asthamatics and human subjects with...
γ-tocopherol (γ-T) alone or in combination with α-tocopherol has been shown to suppress biomarkers of oxidative stress in asthamatics and human subjects with...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1693
SubjectTerms Animals
antioxidant detoxifying enzymes
Antioxidants - metabolism
Antioxidants - pharmacology
Blotting, Western
Diet
Disease Models, Animal
gamma-Tocopherol - therapeutic use
Immunohistochemistry
Male
Metabolic Detoxication, Phase II
Mice
NF-E2-Related Factor 2 - metabolism
Nrf2
oxidative stress
Oxidoreductases - metabolism
prostate cancer
Prostatic Neoplasms - diet therapy
Prostatic Neoplasms - prevention & control
Reverse Transcriptase Polymerase Chain Reaction
RNA - analysis
Tocopherols - therapeutic use
Title γ‐Tocopherol‐enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.24106
https://www.ncbi.nlm.nih.gov/pubmed/19115203
https://www.proquest.com/docview/20628494
https://www.proquest.com/docview/66879415
https://pubmed.ncbi.nlm.nih.gov/PMC4699658
Volume 124
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NTtwwEB4hDqgXChTapfxEFYdesiRe29mopxUCUaStKrRIHCpFtuMtoTRZdbNS1ROPwLvwHn0InoQZ5we2FKnqxUrkseKfGc_nePwZYM-K1PaVNmjiqfU5yvhaYCKZVTwiBOx4uoef5PEZPzkX5wvwoTkLU_FDtD_cyDLcfE0GrvR0_4E0NLs0XXQ_jm6bYrUIEJ221FEEdGoG5sDHhZhsWIUCtt-WnPdFTwDm0zjJx_jVOaCjl_ClqXoVd_KtOyt11_z6g9XxP9u2Ass1MPUGlSatwoLN12BpWG-9v4Lk9-3d9c2oMI6IoLjCF1Q9CiRNve_ZT0zLNs9LM1t6WX6R6aycehM6WYKY1jN0cVFefKX5NZuigDc6HQw_Y3lj1-Hs6HB0cOzXtzP4huMa0u_1ibqMa96zVsQi0lpGErsKAYfSKohZZGwYxmpMWiCUTOPYjGMtVYQrLKZ1bwMW8yK3b8ATTHE-juSYhylngVHaaq5oMSpSjviyA--bcUpMTV1ON2hcJRXpMkuwwxLXYR1414pOKr6OvwntNoOdoDXRFonKbTGbJoyOlPKYPy8hZR-nsFB04HWlHA-fQb8hWNDrQDSnNq0AMXnP5-TZhWP05jImEh5sp9OK52uefDw5cA-b_y76Fl40W2BBuAWL5Y-Z3UYkVeodZzL3LF8e6A
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwEB1VRQJeyh2WWyPEAy_ZJl7b2Uh9qSqqbelWqNpKfUGW7XjbQJtUbFZCPPEJ_Zf-Rz-CL2HGuZSlVEK8RIk8VnyZsc_4cgbgrROZG2pj0cQzF3KUCY3Ah2RO84QQsOfpHu_J0QHfORSHS7De3oWp-SG6BTeyDD9ek4HTgvTaFWto_tn2cf4hvu1bFNHbO1T7HXkUQZ2GgzkK0RWTLa9QxNa6rIuz0TWIef2k5O8I1k9BW_fgU1v4-uTJl_68Mn37_Q9ex_-t3X1YabBpsFEr0wNYcsVDuD1udt8fgbq8-PnjfFJaz0VQnuAHah-dJc2C0_wbPqsuLchyVwV5cZybvJoFZ3S5BGFtYCl2UVEe0RCbz1AgmOxvjD9ifusew8HW-8nmKGwCNISWoxsZDobEXsYNHzgnUpEYIxOJbYWYQxsdpSyxLo5TPSVFEFpmaWqnqZE6QSeLGTN4AstFWbhnEAimOZ8mcsrjjLPIauMM1-SPiowjxOzBu7ajlG3YyymIxomqeZeZwgZTvsF68KYTPaspO_4mtNr2tkKDol0SXbhyPlOMbpXylN8sIeUQR7FY9OBprR1Xv8GpQ7Bo0INkQW86ASLzXkwp8mNP6s1lSjw8WE-vFjeXXG3vbPqX5_8uugp3RpPxrtrd3vvwAu62O2JR_BKWq69z9wqBVWVee_v5Be6PIwM
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NTtwwEB4hkFAvLf1f-kNU9dBLlsRrOxv1hKAroF2E0CJxqGTZjgNpIVl1sxLi1Efou_Q9-hB9ks7kj24pUtWLlchjxT8znm9i-zPAaycSN9TGooknzuco4xuBiWRO84gQcMXTPT6Qu8d8_0ScLMHb9ixMzQ_R_XAjy6jmazLwaZJuXpOGZp9sH90P0W2vcBkMSaV3jjruKEI6DQVz4GMkJltaoYBtdkUXndENhHlzo-TvALbyQKN78LGte73x5HN_Xpq-vfqD1vE_G7cGdxtk6m3VqnQfllz-AFbHzdr7Q1A_vv_8-m1S2IqJoDjHF9Q92kmaeBfZJaZll-clmSu9LD_LTFbOvCkdLUFQ61m6uSgvTmmCzWYo4E2OtsaHWN66R3A8ejfZ3vWb6xl8yzGI9AdD4i7jhg-cE7GIjJGRxK5CxKGNDmIWWReGsU5JDYSWSRzbNDZSRxhiMWMGj2E5L3L3FDzBNOdpJFMeJpwFVhtnuKZoVCQcAWYP3rTjpGzDXU5XaJyrmnWZKewwVXVYD151otOasONvQhvtYCs0J1oj0bkr5jPF6Ewpj_ntElIOcQ4LRQ-e1Mpx_Rl0HIIFgx5EC2rTCRCV92JOnp1VlN5cxsTCg-2stOL2mqu9_e3qYf3fRTdg9XBnpD7sHbx_Bnfa5bAgfA7L5Ze5e4GoqjQvK-v5BZqvIbs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%CE%B3%E2%80%90Tocopherol%E2%80%90enriched+mixed+tocopherol+diet+inhibits+prostate+carcinogenesis+in+TRAMP+mice&rft.jtitle=International+journal+of+cancer&rft.au=Barve%2C+Avantika&rft.au=Khor%2C+Tin+Oo&rft.au=Nair%2C+Sujit&rft.au=Reuhl%2C+Kenneth&rft.date=2009-04-01&rft.issn=0020-7136&rft.eissn=1097-0215&rft.volume=124&rft.issue=7&rft.spage=1693&rft.epage=1699&rft_id=info:doi/10.1002%2Fijc.24106&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_ijc_24106
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0020-7136&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0020-7136&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0020-7136&client=summon